Tue09172019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Writing Service Review
    Writing Service Review
  • Youtube Marketing Guide
    Youtube Marketing Guide
  • Slot Game Review
    Slot Game Review
  • Download TV Series
    Download TV Series
  • All Elite Wrestling
    All Elite Wrestling

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting


-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 --
-- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019 --
MENLO PARK, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that promising initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be presented in a poster discussion session at the 2019 ASCO Annual Meeting in Chicago, Illinois, May 31-June 4, 2019. Presentation Title: The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date & Time: Monday, June 3, 2019 from 4:30 p.m. – 6:00 p.m. CT (5:30 p.m. – 7:00 p.m. ET)
Abstract Number: 7009
Location: Poster Board #384, Hall A, McCormick Place
The accepted abstract is now available online on the ASCO website: https://iplanner.asco.org.Forty Seven’s Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of AML and MDS is funded in part by a research grant awarded by the California Institute for Regenerative Medicine (CIRM).Investor Event and Webcast InformationForty Seven will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to review the initial clinical data presented at ASCO for 5F9. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at www.fortyseveninc.com. A replay of the webcast will be available approximately two hours after the event and will be available for ...


Posted: 2019-05-15 21:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

5 million gift will help create Edward P. Evans Center for MDS at Dana-Farber

Tue, 17 Sep 2019 09:12:00 GMT

Evans Center for Myelodysplastic Syndromes (MDS ... and at least 20% of patients with MDS will develop acute myeloid leukemia (AML). The only possible cure for MDS is a stem cell (bone marrow) ...

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Mon, 22 Apr 2019 04:51:00 GMT

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in ...

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes

Thu, 17 Jan 2019 06:38:00 GMT

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome ... Prognostic impact of molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on ...

How does acute myeloid leukemia (AML) develop in patients exposed to chemotherapy agents?

Tue, 04 Dec 2018 16:00:00 GMT

[Medline]. Cortes JE, et al. A phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic ...

Acute Myeloid Leukemia - Classification

Sun, 06 May 2018 17:00:00 GMT

Patients ... Acute leukemias of ambiguous lineage: Acute leukemias of ambiguous lineage (also known as mixed phenotype acute leukemia) are a subtype of Acute Leukemia where the leukemic cells can not ...

Related News Story Videos From Youtube

Myelodysplastic Syndrome (MDS) | Between The Normal and The Acute Leukemia


Related Videos On: Myelodysplastic Syndrome (MDS) | Between The Normal and The Acute Leukemia


Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia


Related Videos On: Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia


Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)


Related Videos On: Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)


Sorafenib plus GCLAM yielded 83% complete response rate in AML, MDS


Related Videos On: Sorafenib plus GCLAM yielded 83% complete response rate in AML, MDS


David Sallman: Early Results of 5F9 in AML and MDS


Related Videos On: David Sallman: Early Results of 5F9 in AML and MDS







Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.